| |
|
|
Session 91
Poster Presentations Incidence, Prevalence, and Impact of Body Composition Abnormalities Thursday 1:30 - 3:30 pm Hall B |
| 730 | CD4, Viral Load, and HAART Use Independently Predict Longitudinal Body Composition Alterations A.Y. McDermott*1, A. H. Shevitz1,2, N. Terrin2, S. Skinner1, T. Knox2 1Tufts Univ, Boston MA and 2Tufts-New England Med Ctr, Boston, MA |
| 731 | An Objective Comparison of Physician- and Patient-rated Severity of HIV Lipodystrophy A. Carr*1, R. Puls2, M. Law2, HIV Lipodystrophy Case Definition Study Group2 1St Vincent's Hosp, Sydney, Australia and 2Natl Ctr HIV Epidemiology Clin Res, Univ of New South Wales, Sydney, Australia |
| 732 | Lipoatrophy is the Dominant Feature of the Lipodystrophy Syndrome in HIV-infected Men B. Gripshover*1, P. C. Tien2, M. Saag3, D. Osmond2, P. Bacchetti2, C. Grunfeld for the Investigators of the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study2 1Univ Hosp of Cleveland, Case Western Reserve Univ, OH; 2Univ of California at San Francisco; and 3Univ of Alabama at Birmingham |
| 733 | Body Composition in HIV+ men with and without Peripheral Lipoatrophy is Different than Controls M. Saag*1, P. C. Tien2, B. Gripshover3, D. Osmond2, P. Bacchetti2, C. Grunfeld for the Investigators of the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study2 1Univ of Alabama at Birmingham; 2Univ of California at San Francisco; and 3Univ Hosp of Cleveland, Case Western Reserve Univ, OH |
| 734 | Buffalo Hump in Men with HIV Infection: Larger, but Not More Common A. Zolopa*1, C. Benson2, P. Bacchetti3, P. C. Tien3, C. Grunfeld for the Investigators of the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study3 1Stanford Univ, Palo Alto, CA; 2Univ of Colorado, Denver; and 3Univ of California at San Francisco |
| 735 | Body Composition and Antiretroviral Use in Older HIV-infected Women A. A. Howard*, R. Freeman, N. Santoro, E. E. Schoenbaum Montefiore Med Ctr and Albert Einstein Coll of Med, Bronx, NY |
| 736 | Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study P. C. Tien1, S. R. Cole2, C. M. Williams3, R. Li2, J. Justman4, M. H. Cohen5, M. Young6, N. Rubin7, M. Augenbraun8, C. Grunfeld*1 1Univ of California at San Francisco; 2Johns Hopkins Univ, Baltimore, MD; 3Natl Inst of Allergy and Infectious Diseases, NIH, Bethesda, MD; 4Bronx-Lebanon Hosp Ctr, Bronx, NY; 5Cook County Hosp, Chicago, IL; 6Georgetown Univ Med Ctr, Washington, DC; 7Univ of Southern California, Los Angeles; and 8State Univ of New York-Downstate Med Ctr, Brooklyn |
| 737 | Impact on Fat Loss of ZDV + 3TC Backbone: Abdominal CT-scan Sub-study of Study DMP 266-006 K. Tashima*1, J. Morales-Ramirez2, D. Butcher3, C. Barros4, J. Maa5, L. Bessen6, E. Aznar5 1Miriam Hosp,Providence RI; 2San Juan, PR; 3Univ of Missouri-Kansas City Med Sch and the Kansas City AIDS Res Consortium; 4Hosp de Móstoles, Madrid, Spain; 5Bristol-Myers Squibb (BMS), Plainsboro, NJ; and 6BMS, Lawrenceville, NJ |
| 738 | Lipodystrophy in Patients Switched to Indinavir/Ritonavir 800/100 mg BID and Efavirenz 600 mg QD after Failing Nucleoside Combination Therapy: A Prospective, 48-week Observational Sub-study of HIV-NAT 009 M. Boyd*1, D. Bien2, P. van Warmerdam 3, E. Hassink 3, P. Srasuebkul4, N. Chomchey4, T. Methanukroh4, B. Sopa4, S. Wangsuphachart5, A. Krisanachinda5, K. Ruxrungtham6, J. Lange3, D. Cooper1, P. Phanuphak6, P. Reiss7 1HIV Netherlands Australia Thailand Res Collaboration, Thailand NCHECR, Univ of Sydney, Australia; 2Univ of Denver, CO; 3HIV Netherlands Australia Thailand Res Collaboration, Thailand IATEC, Univ of Amsterdam, The Netherlands; 4HIV Netherlands Australia Thailand Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 5Chulalongkorn Univ, Bangkok, Thailand; 6HIV Netherlands Australia Thailand Res Collaboration, Thailand Chulalongkorn Univ; and 7Intl Antiviral Therapy Eval Ctr, Univ of Amsterdam, The Netherlands |
| 739 | Relation between Use of Nucleoside Reverse Transcriptase Inhibitors, Mitochondrial DNA Depletion, and Severity of Lipoatrophy: Results from a Randomized Trial Comparing Stavudine and Zidovudine-based Antiretroviral Therapy M. van der Valk*1, M. Casula1, J. P. Ruiter2, C. van Kuijk2, B. L. F. van Eck-Smit2, G. J. Weverling2, H. J. Hulsebosch2, A. van Eeden3, K. Brinkman4, J. M. A. Lange1,2, R. J. Wanders2, A. de Ronde5, P. Reiss2 1Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 2Academic Med Ctr, Amsterdam, The Netherlands; 3Jan van Gooyen Kliniek, Amsterdam, The Netherlands; 4Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; and 5Primagen, Amsterdam, The Netherlands |
| 740 | Increased Cost of Lipodystrophy in HIV Patients Due to Higher Physician, Laboratory, and Medication Costs M Mugavero*, R Chen, A Westfall, G Cloud, J Raper, K Taylor, J Carter, M Pisu, J Allison, M Saag Univ of Alabama at Birmingham |